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cell-platelet, tumor cell-endothelial cell, and tumor cell-ECM4 inter
actions (9â€”13).The integrin aIIbj33 is expressed in human colon
adenocarcinoma (14), prostate, melanoma, and breast cancer cell
lines,5 suggesting that a11bf33may play an important role in tumor
progression and metastasis.
Given the importance of integrins in various steps of the metastatic
cascade, it is logical that factors that regulate integrin expression and
function may have a significant impact on the metastatic process.
Integrin expression is controlled at the transcriptional level as well as
the posttranscriptional levels. Several transcriptional regulators of
integrin gene expression have been reported in the literature. Regu
lators such as transforming growth factor @3(15), interleukin I (16),
IFN--y (17), tumor necrosis factor-a (17), basic fibroblast growth
factor ( 18), and platelet-derived growth factor ( 19) positively or
negatively regulate integrin gene expression. However, these regula
tors requiretreatmentof severalhours to days to alter integrin gene
expression. A more rapid form of integrin regulation is at the post
transcriptional level. This change in integrin expression is qualitative
because it involves receptor translocation from an intracellular pool to
the plasma membrane and vice versa. Mechanisms involved in post
transcriptional regulation of integrins are not as well characterized as
the transcriptional regulators. Previous data demonstrate that treat
ment of tumor cells with the 12-LOX metabolite of arachidonic acid,
12(S)-HETh, induces posttranscriptional surface expression of inte
grins within 15 mm (9, 10, 20â€”22).This effect is achieved primarily
by increased translocation of the integrin from the cytoplasm to the
cell surface (22). In addition, 12(S)-HETh is also capable of activat
ing transcription of integrin genesas reported for av gene expression
in microvascular endothelial cells (23).
Cumulative reports demonstrate that 12(S)-HETh is involved in all
of the three major aspects of tumor cell invasion, i.e., adhesion,
release of matrix degradative proteinases, and motility (2, 9, 10, 22).
Exogenous 12(S)-HETh stimulates tumor cell motility (24), whereas
endogenously generated 12(S)-HETh mediates motility in responseto
AMF (25). AMF is a member of a family of tumor cell cytokines that
stimulates motility (26) via a receptor-mediated signaling pathway
(27â€”30).Signal transduction following AMF binding to its cell sur
face receptor, gp78 (AMFR), is mediated by a pertussis toxin-sensi
tive G protein (31), phosphorylation of gp78 itself (28), inositolphos
phate production (32), and activation of 12-LOX-mediated signaling,
which involves activation of PKC (24, 25). Since AMF activates the
12-LOX signaling pathway, we questioned whether it could also
regulate integrin expression and function. In this report, we provide
evidence that AMF not only regulates motility, but it also modulates
integrin-mediated tumor cell adhesion, spreading, and invasion.
4 The abbreviations used are: ECM, extracellular matrix; AMF, autocrine motility
factor; COX, cyclooxygenase; 12-LOX, 12-lipoxygenase; PFA, paraformaldehyde; mAb,
monoclonal antibody; PKA, cyclic AMP-dependent kinase; PKC, protein kinase C;
I2(S)-HETE, l2-(S)-hydroxyeicosatetraenoic acid; BHPP, N-benzyl-N-hydroxy-5-
phenylpentanamide;SFM, serom-freemedia;ASA, acetylsalicylicacid.
5 Trikha, M., Chen, Y. Q., Timar, J., Szekeres, C., Bazaz, R., and Horns, K. V.,
unpublished observations.
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ABSTRACT
The binding of autocrine motility factor (AMF) to its cell surface
receptor, gp78, stimulates tumor cell motility. In this report, we provide
evidence that stimulation of gp78 by either AMF or a monoclonal anti
body to gp78 (3F3A) increases adhesion and spreading of metastatic
murine melanoma (B16a) cells on fibronectin. This gp7S-regulated in
crease is mediated by up-regulation of surface aIIbfi3 and a5@31integrin
receptors. In addition, AMF treatment of B16a cells increased transloca
tion of allbfI3 and a5fil from the cytoplasm to the cell surface. However,
aIIbI@3and a5@1 demonstrate separate and unique staining patterns at
the surface of B16a cells in response to stimulation of gp7S. Furthermore,
stimulation of B16a cells with AMF increased their invasion through
MatrigeL This stimulated invasion was inhibited by antibodies to a1Th133
but not by antibodies to aSfil. The increased integrin surface expression
and function in response to AMF was blocked by N.benzyl-N.hydroxy-5-
phenylpentanamide, an inhibitor of 12-lipoxygenase, and calphostin C, an
Inhibitor of protein kinase C. The results demonstrate that AMF stimu
lates integrin-mediated B16a cell adhesion, spreading, and invasion, and
these events are regulated by a signaling pathway involving 12-lipoxyge
nase and protein kinase C.
INTRODUCTION
Metastasis is a complex, yet well co-ordinated, process that can be
defined by a series of integrated events ( 1): (a) tumor cells must
adhere and spread on the extracellular matrix; (b) proteinases are
necessary to degrade the matrix; and (c) tumor cells must migrate
through the degraded matrix. Adhesion and spreading of tumor cells
on the matrix is primarily mediated by integrins (1â€”4).These recep
tom also play a pivotal role in initiating the proteolytic degradation of
the matrix (5), thereby facilitating tumor cell invasion.
The @land (33 subfamilies of integrins play an important role in
tumor invasion and dissemination (6). Qualitative and quantitative
changes in expression of the fibronectin receptor (a5/31) are involved
in the proliferative response of quiescent human melanoma cells (5,
7), whereas overexpression of /33 integrins directly correlates with
metastatic potential in melanoma (2). The integrin aIIb(33 initially
was believed to be expressedonly on platelets (3). However, by using
reverse transcription-PCR, Northern and Southern blotting, and im
munoprecipitation, we demonstrated that this integrin receptor is
expressedon metastatic B 16amelanoma cells (8). Furthermore, it was
demonstrated that this receptor plays an important role in tumor
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AMF REGULATES INTEGRIN EXPRESSION AND FUNCI'ION
mouse IgG conjugated to biotin (1:100 dilution) and streptavidin-Texas Red.
Stained cells were visualized through a Nikon epifluorescence microscope at
x 100 magnification and photographed on KOdakTmax 400 black and white
film. Direct labeling of B16a cells with secondary antibody-biotin conjugate
and streptavidin-Texas Red exhibited no significant background staining.
B16a MelanomaCell InvasionthroughMatrigel. Thisassaywasper
formed in Matrigel-coated Biocoat polycarbonate filter inserts (4 @.tm;Collab
orative Research, Bedford, MA). These inserts were placed on top of 500 @d
of AMF containing SFM in a 24-well plate. B16a cells (5 X l0@'/200Ml) in
SFM were added to the upper chamber of the insert. Tumor cells were
incubated in a tissue culture incubator for 12 h. Following incubation, tumor
cells in the upper chamber were scraped off, and the bottom of the polycar
bonate filter was stained with Diffquick solution (American Scientific Prod
ucts, McGraw Park, IL). The filter was removed from the insert and mounted
on glass coverslides. Tumor cells that migrated through the insert were counted
undera light microscope.Eachdatapoint wasperformedin triplicate.
Drug Treatment of B16a Cells. H8 (Seigaku America, Rockville, MD)
was used to inhibit PKA activity at a concentration of 50 @LM(10). Calphostin
C (Calbiochem,La Jolla, CA) at a concentrationof 5 @Mwas used to inhibit
PKCactivity(24). ASA (300 ELM;Ref. 10) andBHPP(I pM;Refs. 10 and34)
were used to inhibit COX and 12-LOXactivity, respectively. Optimal inhibitor
concentrations were determined in previous experiments reported in the above
cited references.
RESULTS
Effect of AMF on B16a Cell Adhesion and Spreading on Im
mobilized Fibronectin. B16a cells (2 X l0@/ml) after treatment with
various concentrationsof AMF were added to fibronectin-coated
wells, and the cell adhesion assay was performed as described in
â€œMaterialsand Methods.â€•The number of adherent cells per unit area
was counted through a phase contrast microscope. AMF in a dose
dependent manner stimulated adhesion of B16a cells to immobilized
fibronectin (Fig. 1A). Maximum AMF-stimulated adhesion to fi
bronectin was observed at a concentration range of 0.5â€”2.5ng/ml.
Since AMF stimulated B16a cell adhesion to fibronectin, we ques
tioned whether it also could influence cell spreading. AMF in a
dose-dependent manner increased spreading of B 16a cells on fi
bronectin (Fig. 1B). At dosesofO.25â€”2.5ng/ml, AMF induced greater
than an 8-fold increase in cell spreading as compared to spreading in
the absenceof AMF.
aIIb@33andaSfll AreInvolvedin AMF-stimulatedB16aCell
Adhesion to Immobilized Fibronectin. To determine which inte
grins are involved in AMF-stimulated B16a cell adhesion to fibronec
tin, we used adhesion blocking mAbs to the @31and J33subfamilies of
integrins. Both mAbs to the @land to the (33integrins inhibited basal
cell adhesion to fibronectin (in the absence of gp78 stimulation) as
well as gp78-stimulated cell adhesion (Fig. 2). These findings suggest
that AMF-stimulated B16a cell adhesion to fibronectin may involve
both the f31 and f33 subfamily of integrins. To further determine which
integrin receptor within the /33 subfamily is involved in AMF-stim
ulated cell adhesion, we used adhesion blocking antibodies to aIIbf33.
mAbs to alib (AP-4; Fig. 2) and aIIb(33 (AP-2; data not shown) block
AMF-stimulated cell adhesion to fibronectin. Furthermore, antibodies
to the fibronectin receptor (polyclonal antibody to a5@l ; data not
shown) and mAb 1 (anti-aS) also inhibit AMF-stimulated B16a cell
adhesion to fibronectin (Fig. 2). Adhesion blocking antibody to avf33
was not used becausewe have determined previously that these cells
lack av message(8). These results, collectively, suggestthat B16a cell
adhesion to fibronectin in the presence or absence of AMF involves at
least the a5@1and aIIbj33 integrin receptors.
AMF Treatment of B16a Cells IncreasesSurface Expressionof
aIIbj33 and aSÃ˜l. Flow cytometry was usedto determinewhether
the AMF-induced increase in adhesion and spreading was mediated
by an up-regulation of aSf3l and/or aIIb@33.Tumor cells were treated
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MATERIALS AND METHODS
Murine Melanoma Cell Culture. Munne B 16a melanoma cells were
obtained from the Animal and Human Tumor Bank National Cancer Institute
(Frederick, MD). Tumor cells were cultured in RPMI containing 5% fetal
bovine serum (Life Technologies, Inc., Bethesda, MD) and antibiotics (22).
Confluent cells were harvested with 0.45 M EDTA and HBSS (EDTAIHBSS).
AMF Purification. AMF was purifiedfrom HT1O8Ohumanfibrosarcoma
conditioned media as described previously (24). Briefly, semiconfluent
HT1O8Ocells were washedwith PBS and cultured in SFM for 24 h. This
medium was replaced with fresh SFM, which was collected after 24 h.
Conditionedmediumwas pooled, centrifuged,concentrated,and purifiedby
molecular sieve chromatography as described (24).
Antibodies. Rat monoclonal 1gM antibody (3F3A), which stimulates AMF
receptor (gp78) signaling, was prepared as described previously (27). Adhe
sion blocking mAb to the fibronectin receptor (anti-a5) was purchased from
Oncogene Science (Uniondale, NY). A polyclonal antibody to the fibronectin
receptor a5f3l and mAb to the (31 integrin subunit were purchased from Life
Technologies, Inc. Nonimmuneratserumor IgG (MOPC21) was purchased
from Sigma Chemical Co. (St. Louis, MO). AP-4 (m.Ab to olIb; Ref. 8),
OPG-2 (mAb to @3;Ref. 8), and AP-2 (mAb to aI1b@3complex; Refs. 8 and
33) were generousgifts from Dr. ThomasKunicki (The ScrippsResearch
Institute, La Jolla, CA).
Tumor Cell Adhesion and Spreading Assay. Bl6a cells in exponential
growth phase were harvested with EDTA/HBSS and washed extensively with
SFM. After washing, tumor cells were incubated at 37Â°Cfor 1 h prior to
platingonfibronectin(5 g.@g/well)-coated24-wellplates.Fibronectincoatingof
24-well plates was performed by air drying wells containing 5 @gof protein in
PBS. Followingincubation,Bl6a cells (l0@cells/500 ,.dSFM)were incubated
on the fibronectin-coated well for 60 mm at 37Â°C.After incubation, wells were
washed three times with PBS to remove nonadherent cells. The remaining
adherent cells were fixed with 1%PFAIPBS for 10 mm. Two approaches were
used to quantitate the number of adherent cells: (a) adherent cells per unit area
were counted using a phase contrast microscope (X200); (b) adherent cells
werestainedwithGiemsastainfor5 mm,afterwhichexcess stainwas washed
off, and absorbance at 600 nm was recorded by a Bio-Rad plate reader (Model
3550; Bio-Rad, Richmond, CA).
Cell spreading was determined as described previously (10). Briefly, ad
herent cells were examined under X400 magnification, and the cell population
was divided into round, intermediate, and fully spread groups. The spreading
factor was calculated by obtaining a ratio of the number of spread to corn
pletely round cells. Three randomly selected areas per well were counted. For
every data point, at least 100 cells were counted, and each data point was
performed in triplicate.
Flow Cytometry of B16a Cells. Bl6a cells weredetachedwith EDTA/
HBSS, washedthreetimeswithSFM,andallowedto recoverfor 1h in a tissue
culture incubator. Bl6a cells (I X 106)were treated with 3F3A (20 @.tg/ml)or
nonimmune rat serum (I :25 dilution) for 15 mm at 37Â°C and subsequently
washed with SFM and fixed with 1% PFA/HBSS for 10 mm. After fixation,
cells were blocked with normal goat serum (1:2 dilution) for 30 mm and then
incubated with AP-2 (20 @g/ml)or mAbl (20 @g/ml)for 1 h. Bound primary
antibodywasdetectedwith goat antimouseIgG conjugatedto biotin (1:200
dilution; Amersham, Arlington Heights, IL) and streptavidin-FITC (1:200
dilution; Amersham). Fluorescence of labeled B16a cells (1 X l0@) was
measured in a Coulter Epic flow cytometer (Coulter, Hialeah, FL), and the
mean fluorescence was determined. Background fluorescence of labeled B16a
cells was determined by incubating tumor cells with either nonimmune
rat serum (1:25 dilution) or secondary antibody in the absence of primary
antibody.
Immunofluorescence. B16a cells were plated on a fibronectin-coated glass
surface for 60 mm in the presence or absence of AMF (1.25 ng/ml) or 3F3A
(20 @sg/ml).Intracellular proteins were detected by fixing the cells with a
methanol/acetonesolution at â€”20Â°C(25). Plasma membraneproteins were
detected by fixing tumor cells with 1% PFAIPBS solution for 10 mm. After
fixation,cells were permeabilizedwith 0.5%TritonX-100 for 3 mm at room
temperature. Nonspecific binding was blocked by incubating immobilized cells
with normal goat serum diluted 1:2 in PBS for 30 mm. aIIb@33integrin was
detectedby AP-2(20 @g/ml),andfibronectinreceptor(a5f31)wasdetectedby
mAb 1 (20 pg/mI). Bound primary antibodies were detected with goat anti
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presence or absence of 3F3A (Figs. 4, a and b). 3F3A treatment
dramatically altered the cytoplasmic localization of aS(31. In the
absence of 3F3A treatment, B16a cells demonstrated a distinct pe
rinuclear staining pattern for the fibronectin receptor (Fig. 4a). How
ever, after the addition of 3F3A, the fibronectin receptor stained with
a diffuse cytoplasmic pattern (Fig. 4b). A similar response was
observed for an intracellular aHb@3 pool when adherent B16a cells
were labeled with AP-2 (data not shown). These morphological ob
servations were quantitated by evaluating the ratio of dispersed versus
perinuclear integrin staining in the tumor cell population. Table 1
indicates that treatment of B16a cells with 3F3A increased by 4-fold
3F3A (â€”(â€”(â€”(â€”(â€”(â€”)
Antibody agalnat@ @. c.@ @.
Fig. 2. Inhibition of AMF-stimulated Bl6a cell adhesion to fibronectin by anti-integrin
antibodies. B16a cells were preincubated in the presence or absence of nonimmune
antibody, MOPC21 (20 @sg/ml),or the following adhesion blocking antibodies: anti
fibronectin receptor antibody (anti-aS; mAb 1, 20 @ig/ml),anti-el (20 @g/ml),anti-f33
(OPG-2, 20 @sg/m1),or anti-aIIb (AP-4, 20 @g/ml)in the presenceor absenceof 3F3A (20
@g/m1).A cell adhesion assay was performed as described in â€œMaterialsand Methods.â€•
Adherent cells were stained with Giemsa, and absorbanceat 600 nm was recorded. Results
are expressed as the change in the percentage of adhesion in the presence of various
antibodies with respect to adhesion in the absenceof antibody. Each data point represents
the mean of triplicate determinations; bars. SD.
3F3A (-) (+) (-) (+)
Antibody AP-2 mAbi
Fig. 3. gp78-stimulated increase in integrin surface expression on B16a cells. Bl6a
cells (1 X 106)were treated with normal rat serum (1:25 dilution) or anti-AMF receptor
antibody(3F3A,20 @g/m1)for 15mm.After incubation,surfaceexpressionof allb(33and
a5@l was detected by AP-2 and mAb 1, respectively. Flow cytometry was performed as
describedin â€œMaterialsand Methods.â€•Resultsare expressedas the meanof triplicate
determinations of relative fluorescence; bars, SD.
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Fig. 1. Dose-dependent stimulation by AMF of B16a cell adhesion and spreading on
fibronectin.Bl6a cells (1 X l0@/500p1) weresuspendedin SFM or varyingconcentra
tionsof AMF andaddedin triplicateto 24-well platesprecoatedwith 5 @sgof fibronectin.
A, dose-dependent stimulation of adhesion of B16a cells to fibronectin. A cell adhesion
assaywas performedas describedin â€œMaterialsnd Methods.â€•Resultsare expressedas
the percentage increase in adhesion in the presence of various concentrations of AMF with
respect to adhesion in the absence of AMF. B. dose-dependent stimulation by AMF of
Bl6a cell spreading on fibronectin. Bl6a cells were treated with varying concentrations
of AMF as in A, and a cell spreading assay was performed as described in â€œMaterialsand
Methods.â€•Results are expressed as the increase in spreading factor, which was deter
minedasa ratio of spreadto roundcells.Threerandomareaswerecountedfor adhesion
and spreading, and each data point is expressed as the mean of triplicate determinations;
bars, SD.
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with normal rat serum (1:25 dilution) or 3F3A (an AMF receptor
stimulating antibody) for 15 mm and fixed with 1% PFAIPBS. Sur
face expression of aHbf33 and a5@1 was detected by AP-2 and mAb
1, respectively. 3F3A treatment of B16a cells increased surface cx
pression of both integrin receptors (Fig. 3). These findings suggest
that AMF-increased adhesion and spreading of B16a cells on fi
bronectin may correlate with increased surface expression of aIIb(33
and a5@3l.
Activation of gp78 Differentially Regulates Cell Surface Local
ization of aS@31and allb@33. Flow cytometric analysis indicated that
stimulation of gp78 receptor results in increased surface expression of
a5J31and allb@33.Therefore, we used immunofluorescent staining to
investigate whether this increase in surface expression of a5@l and
aHbj33 was due to receptor translocation from the cytoplasm to the
cell surface. To visualize the intracellular a5@l integrin pool, B16a
cells were fixed with methanol/acetone and labeled with mAb 1 in the
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Fig. 4. Effect of gp78 ligation on cellular local
ization of aHb@33and aSfil on B16a cells. Tumor
cells were incubated on fibronectin-coated cover
slips and stimulated with either nonimmune rat
serum(1:25 dilution), 3F3A (20 @g/ml),or AMF
(1.25 ng/ml) for 60 mm at 37'C. Integrins in the
cytoplasm or at the plasma membrane were de
tected by fixing adherent tumor cells with metha
nol/acetone (a and b) or PFAiTriton (c-f), respec
tively. Following fixation, fibronectin receptor and
aHb@3 were detected by mAb 1 and AP-2, respec
tively. Immunofluorescencewas performedasde
scribed in â€œMaterialsand Methods.â€•Detection of a
cytoplasmic pool of a5@l receptor in untreated
cells (a) and in 3F3A-treatedcells(b). Detectionof
a5@l receptorat theplasmamembranein untreated
cells (c) and in AMF-treated cells (d). Detectionof
a11b133at the plasmamembranein untreatedcells
(e) and in AMF-treated cells (f). Single arrowhead,
integrin localization at the cell periphery; double
arrowhead, integrin localization at areas resem
bling adhesioncontacts.N. nucleus;bar, 10 @.tm.
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the number of cells with a dispersed a5@l pattern and by 7-fold in
cells with a dispersed aIIb(33 pattern, suggesting that stimulation of
gp78 induces translocation of integrins to the cell surface. Another
interpretation of this finding is that AMF treatment induces a change
in cell shape(Fig. 1B) that alters staining of integrin receptors without
inducing translocation of integrins from an intracellular pool to the
cell surface. However, flow cytometry (Fig. 3) indicates that 3F3A
treatment of tumor cells increased surface expression of a5f31 and
aIIbj33, and in addition, it has been reported that membrane translo
cation of integrins can occur during cell spreading (10, 22). These
findings, collectively, suggest that stimulation of gp78 in B16a cells
results in increased cell spreading and translocation of integrins from
the perinuclear zone to the cell periphery.
Since stimulation of gp78 resulted in an increased surface expres
sion of aSfJl and aIIb$33,we determined subcellular staining for these
integrins. Fibronectin-adherent Bl6a cells were permeabilized with
Triton X-l00 and labeled with antibodies to the fibronectin receptor
(mAb 1) or to aIIbj33 (AP-2). B l6a cells in the presenceor absence
of AMF displayed no significant change in subcellular localization of
a5@3l (Figs. 4, c and d). In contrast, labeling of aIIb(33 in untreated
Bl6a cells was dramatically different when compared to AMF-treated
cells. In the absenceof AMF stimulation, staining of aIIbf33 appeared
to be uniformly distributed along the apical cell membrane (Fig. 4e).
In contrast, staining for aIIbf33 in the AMF-treated cells was concen
trated to the peripheral regions of the cell membrane (Fig. 4f). These
results demonstrate that AMF differentially regulates the localization
of a5@3land cxllb(33.
aIIbfi3 Is Involved in AMF-stimulated B16a Invasion through
Matrigel. Since antibodies to a11bf33 and to a5@l inhibited gp78-
stimulated tumor cell adhesion (Fig. 2), we characterized their effect
on tumor cell invasion through Matrigel. AMF (1.25 nglml) stimu
lated Bl6a cell invasion through Matrigel, and antibodies to calib, (33,
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Table I Morphometric analysis of intracellular distribution of aJlb@33and a5j31 in
B/ba cellsâ€•
tively, the data suggest that gp78 signaling is coupled to 12-LOX
activity but not to COX activity.
Effect of PKA and PKC Inhibitors on AMF-stimulated B16a
Cell Adhesion and Spreading. It has been reported that AMF
induced tumor cell motility involves PKC, but not PKA, stimulation
(24, 25); therefore, we questioned whether AMF-stimulated cell ad
hesion was mediated via the PKC or the PKA signaling pathway. To
address this question, H8 was used to inhibit PKA activity, and
calphostin C was used to inhibit PKC activity. Incubation of B16a
cells with calphostin C (5 p.M) resulted in a complete inhibition of
3F3A-induced adhesion of tumor cells to fibronectin, whereas treat
ment of tumor cells with H8 (50 pM) partially blocked 3F3A-stimu
lated Bl6a cell adhesion to fibronectin (Table 3). In addition, cal
phostin C, but not H8, blocked the spreading of Bl6a cells on
fibronectin (Table 3). These findings, in combination with previous
reports (24, 25), suggest that gp78-dependent adhesion, spreading,
and motility are primarily coupled to PKC.
DISCUSSION
Integrins play a critical role in tumor cell growth and metastasisas
a result of their involvement in tumor cell adhesion, spreading, and
3F3A (.) (+) (+) (+)
Drug (.) (.) BHPP ASA
Fig. 6. Inhibition of gp78-induced increase in aIIbf33 integrin expression on B16a cells
by 12-LOX and COX inhibitors. B16a cells (1 X l0@)were incubated with 3F3A (20
@.&g/ml)in the presence of BHPP (1 @sM)or ASA (300 @sM)for 15 mm. Following
incubation, flow cytometry was performed on tumor cells as described in â€œMaterialsand
Methods.â€•Surface expression of aIIb@33was detected by AP-2 (20 @sWml).Results are
expressedas the meanof triplicate determinationsof relative meanfluorescence;bars,
SD.
Table 2 Role of 12-LOX and COX inhibitors in 3F3A-stimulated tumor cell adhesion
and spreading
B16a cells, in the presenceof nonimmune rat serum (1:25 dilution. control) or 3F3A
(20 giglml), were treated with BHPP (I MM),ASA (300 SM), or diluent (ethanol), and the
cells were allowed to adhere to fibronectin. The cell adhesion and spreading assay was
performedas describedin â€œMaterialsand Methods.â€•The resultsare expressedas the
means of triplicate determinations Â±SD.
Control 3F3A
a B16a cells that had adhered to fibronectin were stimulated with 3F3A (20 @sg/ml) or
nonimmunerat serom(1:25 dilution) for 60 mm at 37'C, fixed with methanol/acetone,
and stainedfor the cytoplasmicpool of a5f3l or aI1b@3as describedin â€œMaterialsnd
Methods.â€•
b Dispersion ratio. the intracellular distribution of aIIb@3 and a5@l, was evaluated in
100 cells, and a dispersion ratio was determined. The dispersion ratio was calculated by
obtaining a ratio of the number of cells demonstrating a dispersed intracellular integrin
stainingpattern:thenumberof cellsdemonstratinga perinuclearintegrinstainingpattern.
Data are the means of triplicate determinations Â±SD.
5.
0
U.
0
0
C.)
0
.@
Ez
1200
1000
800
AMF (@) (@) (@) (@) (+) (+)
a Adhesion was obtained by calculating the percentage of change in cell adhesion in
the presence of drug with respect to adhesion in the presence of the control diluent
(ethanol).
b Calculated by obtaining a ratio of the number of spread to round cells that were
adhered to fibronectin.
C ND, not determined.
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Fig. 5. Inhibition of AMF-stimulated invasionby anti-integrinantibodies.B16a cells
(5 X l0'@)were addedto Matrigel-coatedfilters in the absenceor presenceof AMF (1.25
ng/ml) and the following antibodies: nonimmune IgG (MOPC21, 20 @.&g/ml),anti-fl
bronectin receptor (anti-aS; mAb 1, 20 @sg/ml),anti-@3l(20 @gIml),anti-alIb (AP-4, 20
@sg/ml),or anti-f33 (OPG-2, 20 @g/ml).Tumor cell invasion assay was performed as
described in â€œMaterialsand Methods.â€•Results are expressed as the number of cells that
migrated through the Matrigel-coated filter. Each data point is the mean of triplicate
determinations;bars, SD.
and aIIbj33 inhibited this invasion (Fig. 5). However, adhesion
blocking antibodies to the fibronectin receptor (mAb 1) or anti-(31 did
not block AMF-stimulated tumor cell invasion (Fig. 5). The number
of B16a cells that invaded through Matrigel in the absenceof AMF
was so small that the effect of anti-integrin antibodies on basal
invasion could not be determined accurately. These findings suggest
that aIIbf33, but not a5(31, may be involved in AMF-stimulated tumor
cell invasion through Matrigel.
Role of Arachidonic Acid Metabolites in gp78 Signaling. Pre
vious studies demonstrated that AMF stimulates endogenous 12-
LOX protein expression and 12(S)-HETE production (25), sug
gesting that 12-LOX inhibitors may suppress gp78-mediated
signaling. Therefore, events believed to be downstream of gp78-
mediated signaling were classified into the following three cate
gories: integrin expression; adhesion; and spreading. To investi
gate the role of arachidonic acid metabolism in these events, BHPP
(1 @.LM)and ASA (300 p.M) were used as 12-LOX and COX
inhibitors, respectively. Pretreatment of B16a cells (15 mm) with
BHPP inhibited gp78-mediated increasein aIIb(33 surfaceexpres
sion by approximately 50% (Fig. 6). In contrast, ASA (300 @.tM)
treatment of B 16a cells did not inhibit the gp78-mediated increase
in surface expression of aIIb/33 (Fig. 6). In addition, BHPP (1 @.tM),
but not ASA (300 @.LM),blocked gp78-stimulated B16a cell adhe
sion and spreading to immobilized fibronectin (Table 2). Collec
Table3 Roleofprotein kinaseinhibitors in 3F3A-stimulatedB16acelladhesionand
spreadingB
16a cells, in the presence of nonimmune rat serum (1 :25 dilution. control) or3F3A(20
@sg/ml),were treated with H8 (50 ,.LM),caiphostin C (5 @sM),or diluent (ethanol),andthe
cells were allowed to adhere to fibronectin. The cell adhesion and spreading assaywasperformed
as describedin â€œMaterialsand Methods.â€•The resultsare expressedasthemeans
of triplicate determinations Â±SD.Control
3F3ADrug
Adhesion(%)â€œSpreadingfactorâ€•Adhesion(%) SpreadingfactorEthanol
100 Â±9 0.25 Â±0.06 191 Â±14 5.21 Â±1.29H8
ND' ND 132 Â±10 6.05 Â±1.09Calphostin
C ND ND 60 Â±15 0.33 Â±0.09
CellMembrane
AMF REGULATESINTEGRINEXPRESSIONAND FUNCTION
adhesion and spreading is a consequenceof surface up-regulation of
aHbf33and a5f3l. Furthermore,pretreatmentof Bl6a cells with antibod
ies to a5/3l and aIIb[33 abrogateAMF-stimulated tumor cell adhesion,
thereby demonstrating that AMF-stimulated tumor cell adhesion and
spreading involve a5f31 and allb(33. This is in accordancewith our
previous study reporting that l2(S)-HETE-stimulated B16a cell adhesion
andspreadingalsouseallb(33 (10), implying that AMF and l2(S)-HETE
participate in the sameintracellular signaling pathway.
Results from flow cytometry and immunofluorescence indicate that
stimulation of gp78 can induce translocation of both a5j31 and aIIb(33
receptors from the cytoplasm to the cell surface. Interestingly, it
appears that stimulation of gp78 by either AMF or 3F3A, similar to
the addition of exogenous 12(S)-HETh ( 10), differentially regulates
subcellular localization of a5(3l and aIIb(33. Immunofluorescent
staining indicates that AMF treatment of B 16a cells results in no
significant change in subcellular localization of aS(3l . In contrast,
membrane labeling of aIIbf33 after AMF treatment is markedly dif
ferent from the staining of raIIbf33in untreated cells. In the absenceof
AMF, aIIbf33 is uniformly distributed at the apical cell surface,
whereas after AMF treatment, aIIb/33 distinctly localizes to the pe
ripheral region of the cell membrane. Why a5(3l and aIIb(33 localize
differently at the cell surface in responseto AMF is presently unclear.
We speculate that other signaling pathways that do not involve gp78,
12-LOX, and/or PKC may regulate surface distribution of a5/31.
Both AMF and 3F3A stimulate the motility of several metastatic
tumor cells, including Bl6a cells (24, 25, 27â€”29).In this study, we
demonstrate for the first time that AMF stimulates invasion of B16a
cells through Matrigel and that antibodies to aIIbf33, but not to a5(3l,
inhibit this AMF-induced invasion. Seftor el a!. (36) reported that
invasion of human melanoma cells through Matrigel involves av(33
because antibodies to this receptor stimulated invasion. B l6a cells do
not express messagefor av but instead express the aIIb/33 integrin
receptor (8). In contrast with the findings of Seftor et a!. (36), we
observed that antibodies to cxIIbf33 inhibited AMF-stimulated inva
sion of B16a cells through Matrigel. Currently, the role of av(33 in
AMF-stimulated melanoma cell invasion is under investigation in our
a Adhesion was obtained by calculating the percentage of change in cell adhesion in
the presence of drug with respect to adhesion in the presence of the control diluent
(ethanol).
b Calculated by obtaining a ratio of the number of spread to round cells that were
adheredto fibronectin.
C ND. not determined.
migration (1, 2, 7, 35). Therefore, the discovery of signal transduction
pathways that regulate integrin expression and function may have a
major impact on tumor progression and invasion. The 12-LOX me
tabolite of arachidonic acid, 12(S)-HETh, enhancesintegrin-mediated
tumor cell adhesion to endothelial cells (2, 35) and to the ECM (2, 10,
35). Previously, we demonstrated that Bl6a cells possess the integrin
aIIbj33, and they use this receptor to adhere to endothelial cells and to
the subendothelial matrix (9â€”13).This adhesion could be enhanced
with 12(S)-HETh treatment due to the increased translocation of
aIIbj33 from a cytoplasmic pool to the cell surface (9, 22).
The literature indicates that AMF-stimulated tumor cell motility
also can be induced by 12(S)-HETh, and this response is coupled to
12-LOX and PKC signaling events (24, 25). Since this signaling
pathway is involved in integrin expression and function (9, 10, 20â€”
22), we hypothesized that AMF should also enhance integrin expres
sion and function on tumor cells. In this study, we report for the first
time that AMF mimics the 12(S)-HETE-mediated response in tumor
cells in terms of stimulating tumor cell adhesion, spreading, invasion,
and up-regulation of surface integrins. Results from flow cytometry
suggest that the AMF receptor (gp78)-mediated increase in tumor cell
(d)
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Fig. 7. Schematic representation of the proposed â€œautocrinemotility signaling pathwayâ€•that results in integrin-mediated tumor cell adhesion, spreading, and invasion. Signal
transductionbeginswhenAMF bindsto its receptorgp78(a), therebyactivating12-LOX(b), which resultsin theproductionof 12(S)-HETE,andit activatesPKC (c). Activationof
PKC results in translocation of the cytoplasmic pool of integrins (d) and gp78 (e) to the cell surface. Increased integrin expression at the cell surface regulates adhesion, spreading,
andinvasion.Dotted lines indicatethat thesemoleculesarenot directly connectedto eachother.
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laboratory. Nonetheless, these observations imply that av(33 and
a11b133may transmit different intracellular signals during the process
of tumor cell invasion. The finding that antibodies to cs5(3l did not
block AMF-stimulated invasion could be attributed to at least two
possibilities: (a) the concentration of fibronectin in Matrigel may be
too insignificant to support binding of a5(3l on B16a cells; and (b) as
mentioned above, surface localization of a5(31 may not be coupled to
the gp78 signaling cascade.
gp78-stimulated tumor cell adhesion,spreading,and invasion are de
pendent on 12-LOX activity. This is supported by the fact that a selective
12-LOX inhibitor BHPP (10, 34) blocked gp78-mediated increase in
surfaceexpressionof allb(33. Also, BHPP inhibited adhesionandspread
ing of B16a cells on fibronectin. Furthermore, BHPP inhibited AMF
stimulated B16a invasion through Matrigel (data not shown). In contrast,
a COX inhibitor, ASA, had no effect on AMF-stimulated surface up
regulation of allb(33, adhesion,or spreading.These results in combina
tion with previous reports(24, 25) demonstratethat 12-LOX is part of the
gp78 signaling pathway, which is involved in AMF-stimulated tumor cell
adhesion,spreading,and invasion.
Our previous reports demonstratedthat 12-LOX is upstreamof PKC
because12(S)-HFFE activatesPKC (10, 21, 24, 34). Since gp78-medi
ated signaling activates 12-LOX (24, 25), we predicted that ligation of
this receptor should also activate PKC. A PKC inhibitor, calphostin C,
blocks gp78-stimulated tumor cell adhesion and spreading. Furthermore,
AMF treatment of B16a cells induces a translocation of PKC from the
cytoplasm to the peripheral membranes(datanot shown). Thesefindings
suggesthat gp78-mediatedsignalingis coupledto 12-LOX,which in
turn activates PKC in B16a cells. Based on data from this study in
combination with previous reports, we propose the existence of an
â€œautocrinemotility signaling pathwayâ€•involving (Fig. 7): (a) AMF
binding to its receptor gp78; (b) signaling of 12-LOX to synthesize
12(S)-HErE (Fig. 6; Table 2; Refs. 24 and 25); (c) 12(S)-HETE-induced
activation of PKC (10, 21, 24, 34); (d) translocation of PKC from
subcellular structuresto lipid membranes(34); (e) PKC-dependenttrans
location of allb(33, a5(31, and gp78 from intracellular pools to the cell
surface (Fig. 4; Tables 1 and 3; Refs. 22 and 25); and (J) differential
surface localization of a5(3l and allb(33 (Fig. 4) and increasedsurface
expression of gp78 (24), which contributes to enhanced tumor cell
adhesion,spreading,and invasion.
Tumor cell invasion is a complex multistep process that requires
regulated expression of cellular adhesion molecules such as integrins.
Our data demonstrate that in B16a cells, AMF regulates integrin
dependent tumor cell adhesion, spreading, and invasion by using
the 12-LOX-PKC signaling pathway. Detailed analysis of this
signaling pathway will further enhance our understanding of tumor
cell invasion.
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